SIMAP

SIMAP will develop a simulation model of the cancer related MAP-kinase pathway, integrating and analyzing data from various types of resources, which may assist in the development of better cancer treatment.

The completion of the human genome gave hope for a new age of medical understanding, but 4-5 years later costs of drug development are still rising and the success rate has not improved. Drugs that have already hit the market are found to have major side effects not perceived in the past and are often given to patients without discrimination on their likeliness to respond.

Large scale methodologies that thrive in recent years, allowed the industry and academia to gather more information on RNAs and proteins. However, the understanding of the molecular and cellular processes is still lacking, not to mention the connection to the clinical outcome. In order to fully use this data, a comprehensive integration and modelling effort is needed. A systematic rational hypothesis-driven research approach connecting all those levels of information is a much needed computational tool. This is the main goal of SIMAP project.

The ultimate goal of SIMAP is to develop a comprehensive simulation biochemical model of EGFRMAP kinase pathway in connection to cancer clinical information. SIMAP will:

  • Incorporate low-level biochemical modelling of individual molecules;
  • Simulate the behaviour of the pathway;
  • Add genomic and proteomic data;
  • Incorporate individual patients’ responses; and
  • Analyze sub population of responses in the context of the biochemical behaviour and genotype data

For further information, please visit:
http://www.simap-project.org

Project co-ordinator:
Compugen Ltd.

Partners:

  • Aureus Pharma, (FR)
  • Compugen Ltd., (IL)
  • Consejo Superior de Investigaciones Científicas, (ES)
  • Halevi Dweck & Co.Arttic Israel Company Ltd., (IL)
  • Fundacio Institut De Recerca De L'Hospital Universitari Vall D'Hebron, (ES)
  • Fondazione IRCCS Istituto Nazionale Dei Tumori, (IT)
  • The Max-Planck Institute for Infection Biology, (DE)
  • The University of Glasgow, (UK)
  • The Weizmann Institute of Science, (IL)

Timetable: from 01/06 – to 12/08

Total cost: € 4.464.201

EC funding: € 3.126.662

Instrument: STREP

Project Identifier: IST-2004-027265

Source: FP6 eHealth Portfolio of Projects

Most Popular Now

Smartphone Photos can be Used to Detect …

A picture of a person's inner eyelid taken with a standard smartphone camera can be used to screen for anemia, according to a new study published this week in the...

Scottish Health and Care Professionals G…

Scottish health and care professionals across a wide range of clinical settings including NHS Scotland health boards are being given access to an individual's COVID-19 vaccine status through the Orion...

Exscientia Accelerates COVID-19 Drug Dis…

Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the COVID-19 Therapeutics Accelerator. This is to expedite the optimisation of...

It's Going to be Quite a Handover…

Health and social care secretary Matt Hancock has been abruptly replaced by Sajid Javid. The Highland Marketing advisory board consider the huge agenda he is now facing, and what it...

Philips and Cognizant Collaborate to Int…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Cognizant (Nasdaq: CTSH), a world-leading professional services firm, announced a new collaboration to develop end-to-end digital health...

Philips Accelerates Stroke Diagnosis and…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced a strategic partnership agreement with NICO.LAB, a MedTech stroke care company. Together with the recently expanded stroke...

Collaboration Between AbbVie, Biogen an…

The access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE:...

Ethics and Governance of Artificial Inte…

Artificial Intelligence (AI) refers to the ability of algorithms encoded in technology to learn from data so that they can perform automated tasks without every step in the process having...

Fujitsu Announces Support of AWS for Hea…

Fujitsu in the UK has announced its support of the AWS for Health initiative from Amazon Web Services (AWS) by bringing Epic in the Cloud to NHS trusts and UK...

Open Call HORIZON-HLTH-2021-TOOL-06-01: …

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 "Unlocking the full potential of new tools, technologies and digital...

New High-Tech Portal Launched to Speed H…

Researchers at the University of Maryland School of Medicine (UMSOM) launched a new online tool that could more quickly advance medical discoveries to reverse progressive hearing loss. The tool enables...

Artificial Intelligence Models to Analyz…

Artificial intelligence tools and deep learning models are a powerful tool in cancer treatment. They can be used to analyze digital images of tumor biopsy samples, helping physicians quickly classify...